Compositions comprising bacterial strains

Abstract

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.

1 . A composition comprising the bacterium deposited under accession number NCIMB 42380 or a biotype thereof, for use in a method of treating or preventing a disease or condition mediated by IL-17 or the Th17 pathway. 
     
     
         2 . The composition of  claim 1 , wherein the composition is for use in a method of treating or preventing a disease or condition selected from the group consisting of asthma, such as allergic asthma or neutrophilic asthma; arthritis, such as rheumatoid arthritis, osteoarthritis, psoriatic arthritis, or juvenile idiopathic arthritis; multiple sclerosis; neuromyelitis optica (Devic's disease); ankylosing spondylitis; spondyloarthritis; psoriasis; systemic lupus erythematosus; inflammatory bowel disease, such as Crohn's disease or ulcerative colitis; celiac disease; chronic obstructive pulmonary disease (COPD); cancer, such as breast cancer, colon cancer, lung cancer or ovarian cancer; uveitis; scleritis; vasculitis; Behcet's disease; atherosclerosis; atopic dermatitis; emphysema; periodontitis; allergic rhinitis; and allograft rejection. 
     
     
         3 . The composition of  claim 2 , wherein the composition is for use in in a method of treating or preventing asthma, such as neutrophilic asthma or allergic asthma. 
     
     
         4 . The composition of  claim 3 , wherein the composition is for use in a method of reducing neutrophilia or eosinophilia in the treatment of asthma. 
     
     
         5 . The composition of  claim 2 , wherein the composition is for use in in a method of treating or preventing rheumatoid arthritis. 
     
     
         6 . The composition of  claim 5 , wherein the composition is for use in a method of reducing joint swelling in rheumatoid arthritis. 
     
     
         7 . The composition of  claim 2 , wherein the composition is for use in in a method of treating or preventing multiple sclerosis. 
     
     
         8 . The composition of  claim 7 , wherein the composition is for use in a method of reducing disease incidence or disease severity. 
     
     
         9 . The composition of  claim 2 , wherein the composition is for use in a method of treating or preventing cancer, such as lung cancer, breast cancer or liver cancer. 
     
     
         10 . The composition of  claim 9 , wherein the composition is for use in a method of reducing tumour size, reducing tumour growth, preventing metastasis or preventing angiogenesis. 
     
     
         11 . The composition of  claim 2 , wherein the composition is for use in a method of treating or preventing uveitis. 
     
     
         12 . The composition of  claim 11 , wherein the composition is for use in a method of reducing or preventing retinal damage in uveitis. 
     
     
         13 . The composition of any preceding claim, wherein the composition is for use in a method of reducing IL-17 production or reducing Th17 cell differentiation in the treatment or prevention of a disease or condition mediated by IL-17 or the Th17 pathway. 
     
     
         14 . The composition of any preceding claim, wherein the composition is for use in a patient with elevated IL-17 levels or Th17 cells. 
     
     
         15 . The composition of any preceding claim, wherein the biotype has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to the 16s rRNA sequence of the bacterium deposited under accession number NCIMB 42380. 
     
     
         16 . The composition of any of  claims 1 - 14 , wherein the biotype has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:1. 
     
     
         17 . The composition of any preceding claim, wherein the composition is for oral administration. 
     
     
         18 . The composition of any preceding claim, wherein the composition comprises one or more pharmaceutically acceptable excipients or carriers. 
     
     
         19 . The composition of any preceding claim, wherein the bacterial strain is lyophilised. 
     
     
         20 . A food product comprising the composition of any preceding claim, for the use of any preceding claim. 
     
     
         21 . A vaccine composition comprising the composition of any preceding claim, for the use of any preceding claim. 
     
     
         22 . A method of treating or preventing a disease or condition mediated by IL-17 or the Th17 pathway, comprising administering a composition comprising the bacterium deposited under accession number NCIMB 42380 or a biotype thereof. 
     
     
         23 . A cell of the bacterium deposited under accession number NCIMB 42380, or a derivative thereof. 
     
     
         24 . A composition comprising the cell of  claim 23 . 
     
     
         25 . The composition of  claim 24 , comprising a pharmaceutically acceptable carrier or excipient. 
     
     
         26 . A biologically pure culture of the bacterium deposited under accession number NCIMB 42380, or a derivative thereof. 
     
     
         27 . A cell of the bacterium deposited under accession number NCIMB 42380, or a derivative thereof, for use in therapy. 
     
     
         28 . The cell of  claim 27 , wherein the cell is for use in a method defined in any of  claims 1 - 14 .